Article Sidebar
Views PDF: 35
Predictive value of p53 and bcl-2 expression in breast cancer
Main Article Content
Abstract
Background: P53 and Bcl-2 genes products continue to be extensively studied in breast cancer in order to identify prognostic factors and to optimize therapeutic approaches.
Objectives and methods: Immunohistochemistry using the anti- P53 and Bcl-2 antibody was performed on 132 breast carcinoma specimens.
Results: Positive p53 expression was correlated with the bad clinicopathological features. Positive Bcl-2 expression was correlated with the good clinicopathological features. p53 (-) Bcl-2 (+) tends to increase survival time and p53 (+) Bcl-2 (-) tends to reduce the survival time but the difference is not statistically significant.
Conclusions: p53 and Bcl-2 expression are contrast in breast cancer, p53 and Bcl-2 detection provides valuable information for prognosis.
Article Details
References
2. American Cancer Society (2015). Cancer Facts & Figures 2015. 56.
3. Callagy G.M. (2006). Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index. Clinical Cancer Research, 12(8), 2468–2475.
4. Malamou-Mitsi V. (2006). Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Annals of Oncology, 17(10), 1504–1511.
5. Bottini A., Berruti A., Bersiga A., et al. p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients. 9.
6. Fourati-Kharrat A (2003). P53 and Bcl 2 EXpression in Breast Cancer. Prospective Study in Tunisia. Austral-Asian Journal of cancer, , accessed: 05/07/2019.
7. Rolland P., Spendlove I., Madjid Z., et al. (2007). The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. International Journal of Cancer, 120(6), 1311–1317.
8. Tsutsui S., Yasuda K., Suzuki K., et al. (2006). Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. BMC Cancer, 6(1).
9. Dowsett M., Smith I.E., Ebbs S.R., et al. (2007). Prognostic Value of Ki67 EXpression After Short- Term Presurgical Endocrine Therapy for Primary Breast Cancer. JNCI: Journal of the National Cancer Institute, 99(2), 167–170.